You are here

Article Text

Article menu
Download PDFPDF
Letter
Nedd5, a novel autoantigen in systemic sclerosis: is it a marker of more severe disease?
  1. V Riccieri1,
  2. C Alessandri1,
  3. V Germano1,
  4. S Guiducci2,
  5. V Rogai2,
  6. T Colasanti1,
  7. F Delunardo3,
  8. P Margutti3,
  9. E Ortona3,
  10. M Matucci Cerinic2,
  11. G Valesini1
  1. 1
    Department of Clinical Medicine and Therapy, Division of Rheumatology, University Sapienza of Rome, Rome, Italy
  2. 2
    Department of BioMedicine, Division of Rheumatology, AOUC, DENOThe Center, University of Florence, Florence, Italy
  3. 3
    Department of Infective, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
  1. Correspondence to V Riccieri, Division of Rheumatology, Department of Clinical Medicine and Therapy, University Sapienza of Rome, Viale del Policlinico 155, 00161, Rome, Italy; valeria.riccieri{at}uniroma1.it

https://doi.org/10.1136/ard.2009.111302

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Nedd5 is an intracytoplasmic protein of the septin family, expressed on the endothelial cell surface after apoptotic stimuli, thus behaving as an autoantigen in different autoimmune diseases.1 2 Several cellular signalling pathways, acting either in cell cycle regulation or in apoptosis, may be altered by the upregulation of Nedd5 expression.3 4

    Anti-Nedd5 autoantibodies are significantly higher in patients with psychiatric lupus erythematosus and in those affected by systemic sclerosis (SSc).5 Considering that the vascular endothelium has a pivotal position in the pathophysiology of SSc, although the great part of factors provoking the endothelial damage remains unknown,6 the aim of this study was to evaluate anti-Nedd5 serum immunoreactivity responses in patients with SSc and to find out whether it can be associated to the different aspects of this …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Ethics approval Ethics approval was granted by the ethics committee of the Ospedale Policlinico Umberto I of Rome.

    • Provenance and Peer review Not commissioned; externally peer reviewed.